Search

Gerold L Mosher

from Kansas City, MO
Age ~67
Get Report
Also known as:
Garold L Mosher, Gerald L Mosher
Phone and address:
12215 Avila Dr, Kansas City, MO 64145
(816) 941-9541
Related to:
Doris G CoweeRobert L Cowee, 93Jane A Cowee, 62
Connected to:
Almon L Mosher, 82Amy B Mosher, 49Babette M Mosher, 70Darla J Mosher, 53Debra J Mosher, 66Emily A Mosher, 41Harley A Mosher, 54Holly L Mosher, 52Kathleen A Mosher, 76Kendra L Mosher, 75

Gerold Mosher Phones & Addresses

  • 12215 Avila Dr, Kansas City, MO 64145 (816) 941-9541
  • Lawrence, KS
  • Greenwood, IN
  • Indianapolis, IN

Work

Company: Silvergate pharmaceuticals, inc Jan 2013 Position: Vp drug development

Education

Degree: PhD School / High School: University of Kansas 1981 to 1986 Specialities: Pharmaceutical Chemistry

Industries

Pharmaceuticals

Resumes

Resumes

Gerold Mosher Photo 1

Vice President Drug Development

View page
Location:
Kansas City, MO
Industry:
Pharmaceuticals
Work:
Silvergate Pharmaceuticals, Inc since Jan 2013
VP Drug Development
Education:
University of Kansas 1981 - 1986
PhD, Pharmaceutical Chemistry University of Kansas 1976 - 1979
BS, Pharmacy

Business Records

Name / Title
Company / Classification
Phones & Addresses
Gerold Mosher
Director Of Product Development
Cydex Pharmaceuticals, Inc.
Pharmaceutical Preparations
10513 W 84Th Ter, Shawnee Mission, KS 66214
Gerold Mosher
Director, Sales And Marketing Executive, Director Of Product Development
CyDex Pharmaceuticals, Inc.
Pharmaceuticals · Nonclassifiable Establishments · Mfg Pharmaceutical Preparations · Pharmaceutical Preparations
10513 W 84 Ter, Lenexa, KS 66214
2029 Becker Dr, Lawrence, KS 66047
10513 W 84 Ter, Overland Park, KS 66214
(913) 685-8850, (913) 577-5881, (913) 402-3501
Gerold Mosher
Director Of Product Development
Cydex Pharmaceuticals, Inc.
Pharmaceutical Preparations
10513 W 84Th Ter, Shawnee Mission, KS 66214

Publications

Us Patents

Formulations Containing Amiodarone And Sulfoalkyl Ether Cyclodextrin

View page
US Patent:
6869939, Mar 22, 2005
Filed:
May 4, 2002
Appl. No.:
10/139620
Inventors:
Gerold L. Mosher - Kansas City MO, US
Karen T. Johnson - Lawrence KS, US
Atef A. Gayed - Overland Park KS, US
Assignee:
CyDex, Inc. - Lenexa KS
International Classification:
A61K031/724
A61K031/343
US Classification:
514 58, 514469
Abstract:
The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parenteral administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared.

Formulations Containing Propofol And A Sulfoalkyl Ether Cyclodextrin

View page
US Patent:
7034013, Apr 25, 2006
Filed:
Mar 19, 2002
Appl. No.:
10/102066
Inventors:
Diane O. Thompson - Overland Park KS, US
Gerold L. Mosher - Kansas City MO, US
Assignee:
Cydex, Inc. - Lenexa KS
International Classification:
A61K 31/724
A61K 31/04
US Classification:
514 58, 514734
Abstract:
An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL cyclodextrin (sulfobutyl ether β-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.

Sulfoalkyl Ether Cyclodextrin Compositions And Methods Of Preparation Thereof

View page
US Patent:
7629331, Dec 8, 2009
Filed:
Jan 31, 2009
Appl. No.:
12/363719
Inventors:
James D. Pipkin - Lawrence KS, US
Gerold L. Mosher - Kansas City MO, US
Douglas B. Hecker - Liberty MO, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 31/724
C07H 15/04
US Classification:
514 54, 514 58, 536120, 5361231
Abstract:
A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Sulfoalkyl Ether Cyclodextrin Compositions And Methods Of Preparation Thereof

View page
US Patent:
8049003, Nov 1, 2011
Filed:
Apr 23, 2008
Appl. No.:
12/108228
Inventors:
Gerold L. Mosher - Kansas City MO, US
James D. Pipkin - Lawrence KS, US
Douglas B. Hecker - Liberty MO, US
Assignee:
CyDex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
C08B 37/16
C07H 3/06
C07H 15/04
A61K 31/716
A61K 31/718
A61K 31/702
US Classification:
536103, 514 54, 514 58, 536111, 536120, 53612312
Abstract:
A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Dpi Formulation Containing Sulfoalkyl Ether Cyclodextrin

View page
US Patent:
8114438, Feb 14, 2012
Filed:
Oct 19, 2006
Appl. No.:
11/550976
Inventors:
James D. Pipkin - Lawrence KS, US
Gerold L. Mosher - Kansas City MO, US
Douglas B. Hecker - Liberty MO, US
Assignee:
Cydex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 9/00
A61K 9/14
A61K 9/16
US Classification:
424489, 424 46
Abstract:
An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.

Pharmaceutical Compositions Comprising Prasugrel And Cyclodextrin Derivatives And Methods Of Making And Using The Same

View page
US Patent:
8236782, Aug 7, 2012
Filed:
May 13, 2010
Appl. No.:
12/779850
Inventors:
Gerold L. Mosher - Kansas City MO, US
Stephen G. Machatha - Waltham MA, US
Daniel J. Cushing - Phoenixville PA, US
Assignee:
Cydex Pharmaceuticals, Inc. - Lawrence KS
International Classification:
A61K 31/724
A61K 31/4436
US Classification:
514 58, 514301
Abstract:
The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.

Formulations Containing Clopidogrel And Sulfoalkyl Ether Cyclodextrin And Methods Of Use

View page
US Patent:
8343995, Jan 1, 2013
Filed:
Apr 26, 2008
Appl. No.:
12/597908
Inventors:
Gerold L. Mosher - Kansas City MO, US
Rebecca L. Wedel - Lawrence KS, US
Karen T. Johnson - Lawrence KS, US
Stephen G. Machatha - Waltham MA, US
Jane A. Cowee - Kansas City MO, US
Daniel J. Cushing - Phoenixville PA, US
Assignee:
Cydex Pharmaceuticals, Inc. - Lenexa KS
International Classification:
A61K 31/44
US Classification:
514299, 514451
Abstract:
The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution.

Formulations Containing Etomidate And A Sulfoalkyl Ether Cyclodextrin

View page
US Patent:
20030055023, Mar 20, 2003
Filed:
Mar 19, 2002
Appl. No.:
10/102049
Inventors:
Roger Rajewski - Lawrence KS, US
Michelle McIntosh - Lawrence KS, US
Diane Thompson - Overland Park KS, US
Gerold Mosher - Kansas City MO, US
International Classification:
A61K031/724
US Classification:
514/058000
Abstract:
An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection, and is bioequivalent with currently approved formulations. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL cyclodextrin (sulfobutyl ether -cyclodextrin) to form a true aqueous solution. This formulation minimizes the allergic response and microbial contamination issues typically associated with parenteral emulsion formulations. The present formulation also reduces pain on injection as compared to the known organic solvent based formulations containing etomidate. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.
Control profile
Gerold L Mosher from Kansas City, MO, age ~67 Get Report